Last reviewed · How we verify
Lidoderm
At a glance
| Generic name | Lidoderm |
|---|---|
| Also known as | Lidocaine patch 5%, Lidocaine 5% patch, Lidocaine 5% Patch, Lidocaine patach 5%, Lidoderm, Lidoaine patch 5% |
| Sponsor | Endo Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Closed Versus Open Lateral Internal Sphincterotomy for Chronic Anal Fissure (NA)
- OMT for Adhesive Capsulitis (PHASE4)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidoderm CI brief — competitive landscape report
- Lidoderm updates RSS · CI watch RSS
- Endo Pharmaceuticals portfolio CI